New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Purpose HER2 signaling functional activity may be important to measure in addition to HER2 protein quantification when identifying patients eligible for HER2 therapies. A HER2 Signaling Function (CELx HSF) Test for HER2-negative patients uses patient’s live tumor cells on a biosensor to identify pat...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2020-03, Vol.146 (3), p.605-619 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 619 |
|---|---|
| container_issue | 3 |
| container_start_page | 605 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 146 |
| creator | MacNeil, Ian A. Burns, David J. Rich, Benjamin E. Soltani, Sajjad M. Kharbush, Samantha Osterhaus, Nicole G. Sullivan, Brian F. Hawkins, Douglas M. Pietruska, Jodie R. Laing, Lance G. |
| description | Purpose
HER2 signaling functional activity may be important to measure in addition to HER2 protein quantification when identifying patients eligible for HER2 therapies. A HER2 Signaling Function (CELx HSF) Test for HER2-negative patients uses patient’s live tumor cells on a biosensor to identify patients with abnormally high HER2-related signaling (HSFs+) likely to respond to anti-HER2 therapies.
Methods
The CELx HSF test was employed to: (1) characterize the sensitivity and specificity of the test to detect abnormal levels of HER2 signaling; (2) evaluate the inhibitory effectiveness of five different anti-HER2 therapies; (3) assess the correlation between CELx HSF test detection of abnormal HER2 signaling and response to HER2 therapy using xenograft models; and (4) confirm the prevalence of abnormal HER2 signaling amongst HER2-negative breast cancer patients (HER2−/HSFs+).
Results
HER2−/HSFs+ breast cancer patient samples were identified and showed sensitivity to five approved anti-HER2 therapies. Xenograft studies using both HER2+ and HER2− cell lines confirmed that CELx HER2 signaling status better predicts HER2 inhibitor efficacy than HER2 receptor status. In a study of 114 HER2-negative breast tumor patient samples, 27 (23.7%; 95% CI = 17–32%) had abnormal HER2 signaling (HSFs+). A ROC curve constructed with this dataset projects the CELx HSF Test would have greater than 90% sensitivity and specificity to detect the HER2−/HSFs+ patient population.
Conclusions
The CELx HSF test is a well-characterized functional biomarker assay capable of identifying dynamic HER2-driven signaling dysfunction in tumor cells from HER2-negative breast cancer patients. This test has demonstrated efficacy of various HER2 targeted therapies in live tumor cells from the HSFs+ population and correlated the test result to HER2 drug response in mouse xenograft studies. The proportion of HER2-negative breast cancer patients found to have abnormal HER2 signaling in a 114 patient sample study, 20–25%, is significant. A clinical trial to evaluate the efficacy of anti-HER2 therapies in this patient population is warranted. |
| doi_str_mv | 10.1007/s00432-020-03144-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7039866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2362698419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-27ed1f1d4c689c395287ca8e6ed0192e85521de7fac7fa0159f2e51a3681c10a3</originalsourceid><addsrcrecordid>eNp9UVtLwzAUDqLovPwBH6TgczQnSZP2RRCZFxCFoc8hS09nx2xr0k32703tvL34EELO-W7kI-QY2Bkwps8DY1JwyjijTICUVG-REfQjECLdJiMGGmjKQe2R_RDmLL5TzXfJnuBMKJnKEZk84HtyO55wWuPMdtUKk6lHG7rE2dqhT8Jy2q1bTDyGtqlDD-iaxNZdRXta0r2gt-06qQqMs7LC4pDslHYR8GhzH5Dn6_HT1S29f7y5u7q8p05q2VGusYASCulUljuRpzzTzmaosGCQc8zSmLxAXVoXD4M0LzmmYIXKwAGz4oBcDLrtcvqKhYv-3i5M66tX69emsZX5u6mrFzNrVkYzkWdKRYHTjYBv3pYYOjNvlr6OmQ0Xiqs8k5BHFB9QzjcheCy_HYCZvgcz9GBiD-azB6Mj6eR3tm_K18dHgBgAIa7qGfof739kPwCYxJOT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2362698419</pqid></control><display><type>article</type><title>New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>MacNeil, Ian A. ; Burns, David J. ; Rich, Benjamin E. ; Soltani, Sajjad M. ; Kharbush, Samantha ; Osterhaus, Nicole G. ; Sullivan, Brian F. ; Hawkins, Douglas M. ; Pietruska, Jodie R. ; Laing, Lance G.</creator><creatorcontrib>MacNeil, Ian A. ; Burns, David J. ; Rich, Benjamin E. ; Soltani, Sajjad M. ; Kharbush, Samantha ; Osterhaus, Nicole G. ; Sullivan, Brian F. ; Hawkins, Douglas M. ; Pietruska, Jodie R. ; Laing, Lance G.</creatorcontrib><description>Purpose
HER2 signaling functional activity may be important to measure in addition to HER2 protein quantification when identifying patients eligible for HER2 therapies. A HER2 Signaling Function (CELx HSF) Test for HER2-negative patients uses patient’s live tumor cells on a biosensor to identify patients with abnormally high HER2-related signaling (HSFs+) likely to respond to anti-HER2 therapies.
Methods
The CELx HSF test was employed to: (1) characterize the sensitivity and specificity of the test to detect abnormal levels of HER2 signaling; (2) evaluate the inhibitory effectiveness of five different anti-HER2 therapies; (3) assess the correlation between CELx HSF test detection of abnormal HER2 signaling and response to HER2 therapy using xenograft models; and (4) confirm the prevalence of abnormal HER2 signaling amongst HER2-negative breast cancer patients (HER2−/HSFs+).
Results
HER2−/HSFs+ breast cancer patient samples were identified and showed sensitivity to five approved anti-HER2 therapies. Xenograft studies using both HER2+ and HER2− cell lines confirmed that CELx HER2 signaling status better predicts HER2 inhibitor efficacy than HER2 receptor status. In a study of 114 HER2-negative breast tumor patient samples, 27 (23.7%; 95% CI = 17–32%) had abnormal HER2 signaling (HSFs+). A ROC curve constructed with this dataset projects the CELx HSF Test would have greater than 90% sensitivity and specificity to detect the HER2−/HSFs+ patient population.
Conclusions
The CELx HSF test is a well-characterized functional biomarker assay capable of identifying dynamic HER2-driven signaling dysfunction in tumor cells from HER2-negative breast cancer patients. This test has demonstrated efficacy of various HER2 targeted therapies in live tumor cells from the HSFs+ population and correlated the test result to HER2 drug response in mouse xenograft studies. The proportion of HER2-negative breast cancer patients found to have abnormal HER2 signaling in a 114 patient sample study, 20–25%, is significant. A clinical trial to evaluate the efficacy of anti-HER2 therapies in this patient population is warranted.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-020-03144-7</identifier><identifier>PMID: 32036454</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Biomarkers, Tumor - analysis ; Biosensors ; Breast cancer ; Breast Neoplasms - metabolism ; Cancer Research ; Electric Impedance ; ErbB-2 protein ; Female ; Hematology ; Humans ; Internal Medicine ; Medicine ; Medicine & Public Health ; Mice ; Oncology ; Original Article – Cancer Research ; Original – Cancer Research ; Patients ; Receptor, ErbB-2 - metabolism ; Signal Transduction - physiology ; Tumor cells ; Xenograft Model Antitumor Assays ; Xenografts</subject><ispartof>Journal of cancer research and clinical oncology, 2020-03, Vol.146 (3), p.605-619</ispartof><rights>The Author(s) 2020</rights><rights>Journal of Cancer Research and Clinical Oncology is a copyright of Springer, (2020). All Rights Reserved. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-27ed1f1d4c689c395287ca8e6ed0192e85521de7fac7fa0159f2e51a3681c10a3</citedby><cites>FETCH-LOGICAL-c474t-27ed1f1d4c689c395287ca8e6ed0192e85521de7fac7fa0159f2e51a3681c10a3</cites><orcidid>0000-0003-4593-0685</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-020-03144-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-020-03144-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32036454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MacNeil, Ian A.</creatorcontrib><creatorcontrib>Burns, David J.</creatorcontrib><creatorcontrib>Rich, Benjamin E.</creatorcontrib><creatorcontrib>Soltani, Sajjad M.</creatorcontrib><creatorcontrib>Kharbush, Samantha</creatorcontrib><creatorcontrib>Osterhaus, Nicole G.</creatorcontrib><creatorcontrib>Sullivan, Brian F.</creatorcontrib><creatorcontrib>Hawkins, Douglas M.</creatorcontrib><creatorcontrib>Pietruska, Jodie R.</creatorcontrib><creatorcontrib>Laing, Lance G.</creatorcontrib><title>New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
HER2 signaling functional activity may be important to measure in addition to HER2 protein quantification when identifying patients eligible for HER2 therapies. A HER2 Signaling Function (CELx HSF) Test for HER2-negative patients uses patient’s live tumor cells on a biosensor to identify patients with abnormally high HER2-related signaling (HSFs+) likely to respond to anti-HER2 therapies.
Methods
The CELx HSF test was employed to: (1) characterize the sensitivity and specificity of the test to detect abnormal levels of HER2 signaling; (2) evaluate the inhibitory effectiveness of five different anti-HER2 therapies; (3) assess the correlation between CELx HSF test detection of abnormal HER2 signaling and response to HER2 therapy using xenograft models; and (4) confirm the prevalence of abnormal HER2 signaling amongst HER2-negative breast cancer patients (HER2−/HSFs+).
Results
HER2−/HSFs+ breast cancer patient samples were identified and showed sensitivity to five approved anti-HER2 therapies. Xenograft studies using both HER2+ and HER2− cell lines confirmed that CELx HER2 signaling status better predicts HER2 inhibitor efficacy than HER2 receptor status. In a study of 114 HER2-negative breast tumor patient samples, 27 (23.7%; 95% CI = 17–32%) had abnormal HER2 signaling (HSFs+). A ROC curve constructed with this dataset projects the CELx HSF Test would have greater than 90% sensitivity and specificity to detect the HER2−/HSFs+ patient population.
Conclusions
The CELx HSF test is a well-characterized functional biomarker assay capable of identifying dynamic HER2-driven signaling dysfunction in tumor cells from HER2-negative breast cancer patients. This test has demonstrated efficacy of various HER2 targeted therapies in live tumor cells from the HSFs+ population and correlated the test result to HER2 drug response in mouse xenograft studies. The proportion of HER2-negative breast cancer patients found to have abnormal HER2 signaling in a 114 patient sample study, 20–25%, is significant. A clinical trial to evaluate the efficacy of anti-HER2 therapies in this patient population is warranted.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biosensors</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Cancer Research</subject><subject>Electric Impedance</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Oncology</subject><subject>Original Article – Cancer Research</subject><subject>Original – Cancer Research</subject><subject>Patients</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Signal Transduction - physiology</subject><subject>Tumor cells</subject><subject>Xenograft Model Antitumor Assays</subject><subject>Xenografts</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9UVtLwzAUDqLovPwBH6TgczQnSZP2RRCZFxCFoc8hS09nx2xr0k32703tvL34EELO-W7kI-QY2Bkwps8DY1JwyjijTICUVG-REfQjECLdJiMGGmjKQe2R_RDmLL5TzXfJnuBMKJnKEZk84HtyO55wWuPMdtUKk6lHG7rE2dqhT8Jy2q1bTDyGtqlDD-iaxNZdRXta0r2gt-06qQqMs7LC4pDslHYR8GhzH5Dn6_HT1S29f7y5u7q8p05q2VGusYASCulUljuRpzzTzmaosGCQc8zSmLxAXVoXD4M0LzmmYIXKwAGz4oBcDLrtcvqKhYv-3i5M66tX69emsZX5u6mrFzNrVkYzkWdKRYHTjYBv3pYYOjNvlr6OmQ0Xiqs8k5BHFB9QzjcheCy_HYCZvgcz9GBiD-azB6Mj6eR3tm_K18dHgBgAIa7qGfof739kPwCYxJOT</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>MacNeil, Ian A.</creator><creator>Burns, David J.</creator><creator>Rich, Benjamin E.</creator><creator>Soltani, Sajjad M.</creator><creator>Kharbush, Samantha</creator><creator>Osterhaus, Nicole G.</creator><creator>Sullivan, Brian F.</creator><creator>Hawkins, Douglas M.</creator><creator>Pietruska, Jodie R.</creator><creator>Laing, Lance G.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4593-0685</orcidid></search><sort><creationdate>20200301</creationdate><title>New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified</title><author>MacNeil, Ian A. ; Burns, David J. ; Rich, Benjamin E. ; Soltani, Sajjad M. ; Kharbush, Samantha ; Osterhaus, Nicole G. ; Sullivan, Brian F. ; Hawkins, Douglas M. ; Pietruska, Jodie R. ; Laing, Lance G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-27ed1f1d4c689c395287ca8e6ed0192e85521de7fac7fa0159f2e51a3681c10a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biosensors</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Cancer Research</topic><topic>Electric Impedance</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Oncology</topic><topic>Original Article – Cancer Research</topic><topic>Original – Cancer Research</topic><topic>Patients</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Signal Transduction - physiology</topic><topic>Tumor cells</topic><topic>Xenograft Model Antitumor Assays</topic><topic>Xenografts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MacNeil, Ian A.</creatorcontrib><creatorcontrib>Burns, David J.</creatorcontrib><creatorcontrib>Rich, Benjamin E.</creatorcontrib><creatorcontrib>Soltani, Sajjad M.</creatorcontrib><creatorcontrib>Kharbush, Samantha</creatorcontrib><creatorcontrib>Osterhaus, Nicole G.</creatorcontrib><creatorcontrib>Sullivan, Brian F.</creatorcontrib><creatorcontrib>Hawkins, Douglas M.</creatorcontrib><creatorcontrib>Pietruska, Jodie R.</creatorcontrib><creatorcontrib>Laing, Lance G.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MacNeil, Ian A.</au><au>Burns, David J.</au><au>Rich, Benjamin E.</au><au>Soltani, Sajjad M.</au><au>Kharbush, Samantha</au><au>Osterhaus, Nicole G.</au><au>Sullivan, Brian F.</au><au>Hawkins, Douglas M.</au><au>Pietruska, Jodie R.</au><au>Laing, Lance G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>146</volume><issue>3</issue><spage>605</spage><epage>619</epage><pages>605-619</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Purpose
HER2 signaling functional activity may be important to measure in addition to HER2 protein quantification when identifying patients eligible for HER2 therapies. A HER2 Signaling Function (CELx HSF) Test for HER2-negative patients uses patient’s live tumor cells on a biosensor to identify patients with abnormally high HER2-related signaling (HSFs+) likely to respond to anti-HER2 therapies.
Methods
The CELx HSF test was employed to: (1) characterize the sensitivity and specificity of the test to detect abnormal levels of HER2 signaling; (2) evaluate the inhibitory effectiveness of five different anti-HER2 therapies; (3) assess the correlation between CELx HSF test detection of abnormal HER2 signaling and response to HER2 therapy using xenograft models; and (4) confirm the prevalence of abnormal HER2 signaling amongst HER2-negative breast cancer patients (HER2−/HSFs+).
Results
HER2−/HSFs+ breast cancer patient samples were identified and showed sensitivity to five approved anti-HER2 therapies. Xenograft studies using both HER2+ and HER2− cell lines confirmed that CELx HER2 signaling status better predicts HER2 inhibitor efficacy than HER2 receptor status. In a study of 114 HER2-negative breast tumor patient samples, 27 (23.7%; 95% CI = 17–32%) had abnormal HER2 signaling (HSFs+). A ROC curve constructed with this dataset projects the CELx HSF Test would have greater than 90% sensitivity and specificity to detect the HER2−/HSFs+ patient population.
Conclusions
The CELx HSF test is a well-characterized functional biomarker assay capable of identifying dynamic HER2-driven signaling dysfunction in tumor cells from HER2-negative breast cancer patients. This test has demonstrated efficacy of various HER2 targeted therapies in live tumor cells from the HSFs+ population and correlated the test result to HER2 drug response in mouse xenograft studies. The proportion of HER2-negative breast cancer patients found to have abnormal HER2 signaling in a 114 patient sample study, 20–25%, is significant. A clinical trial to evaluate the efficacy of anti-HER2 therapies in this patient population is warranted.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32036454</pmid><doi>10.1007/s00432-020-03144-7</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-4593-0685</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2020-03, Vol.146 (3), p.605-619 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7039866 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Animals Antineoplastic Agents - pharmacology Biomarkers, Tumor - analysis Biosensors Breast cancer Breast Neoplasms - metabolism Cancer Research Electric Impedance ErbB-2 protein Female Hematology Humans Internal Medicine Medicine Medicine & Public Health Mice Oncology Original Article – Cancer Research Original – Cancer Research Patients Receptor, ErbB-2 - metabolism Signal Transduction - physiology Tumor cells Xenograft Model Antitumor Assays Xenografts |
| title | New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T02%3A41%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20HER2-negative%20breast%20cancer%20subtype%20responsive%20to%20anti-HER2%20therapy%20identified&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=MacNeil,%20Ian%20A.&rft.date=2020-03-01&rft.volume=146&rft.issue=3&rft.spage=605&rft.epage=619&rft.pages=605-619&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-020-03144-7&rft_dat=%3Cproquest_pubme%3E2362698419%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2362698419&rft_id=info:pmid/32036454&rfr_iscdi=true |